94 Search Results


Search Again

Anthony DeSantis , MD

Email: ad29@uw.edu

Phone: (206) 598-4882

Dr. DeSantis specializes in Endocrinology focusing on type 1 and type 2 diabetes, adrenal problems, metabolic bone disease, pituitary problems and thyroid problems.

View Bio

Marianne Dubard-Gault , MD, MS

Email: mdg2019@uw.edu

Dr. Dubard-Gault is the medical director of the Cancer Genetics Program at SCCA. Her main research interest is to better understand how genetic information influences patients’ decision-making about health care and life choices. She is also interested in exploring ways to help people better access medical genetic information, talk about it with their families and use that knowledge to make decisions that fit their goals.

View Bio

Robert Eisenman , PhD

Email: eisenman@fredhutch.org

Phone: (206) 667-4445

Dr. Eisenman studies how cell proliferation, growth, and differentiation are regulated through the actions of transcriptional networks, and how this regulation is subverted during tumor progression. Specifically, his laboratory research focuses on gaining a deeper understanding of the mechanisms of an oncogenic transcription factor network (Myc/Max/Mxd) which is fundamental in all cancers.

View Bio

Manuel Ferreira , MD, PhD

Email: manuelf3@u.washington.edu

Phone: (206) 744-932

Dr. Ferreira specializes in the multi-modality treatment for tumors of the skull base, brain and spinal cord, including meningiomas; schwannomas; pituitary tumors; craniopharyngiomas; neurofibromatosis; chordomas and chondrosarcomas; Von Hippel-Lindau; hemangioblastomas; sinonasal tumors of the skull base; and cysts. He uses minimally-invasive skull base procedures to treat these conditions. Moreover he conducts research to understand the genetic basis of these tumors and inherited disorders and wants to use the genetic discovery to predict response to therapy (radio-sensitivity or radio-resistance).

View Bio

Stephen Friend , MD, PhD

Email: friend@sagebase.org

Phone: (206) 667-2101

Dr. Stephen Friend is a world leader in efforts to make large scale, data-intensive biology more openly accessible to citizens and the entire research community in order to accelerate scientific progress. He is a co-founder of Sage Bionetworks, a nonprofit institute working to create an open-access Internet database for researchers worldwide to share their genomic data. Sage bionetworks is hosted by Fred Hutchinson Cancer research Center and its goal to build predictive models of cancer.

View Bio

Jeffrey Russell Geyer , MD

Email: russ.geyer@seattlechildrens.org

Phone: (206) 987-6664

Dr. Geyer treats children who have cancer. He believes that caring for children and adolescents requires an expert team. His research focus is in pediatric brain tumors, with a special emphasis on young children with brain tumors.

View Bio

Barry Gumbiner , PhD

Email: gumbiner@uw.edu

Phone: 206-884-5116

Dr. Gumbiner and his team study how cadherin cell adhesion molecules and associated catenin proteins control tumor development and progression. Cadherins and catenins play important roles in the morphogenesis, maintenance, and regeneration of tissues, and alterations in their functions are important in cancer. One major effort of the laboratory is to understand how cadherins signal into the cell to control growth and differentiation through regulation of both the Wnt-beta-catenin pathway and the Hippo signaling pathway; the latter inhibits cell proliferation and participates in organ size control. Cadherins mediate contact inhibition of growth by stimulating the Hippo pathway, while growth factors, such as EGF, inhibit the Hippo pathway. They are investigating how these modes of regulation of the Hippo pathway affect the development of different types of tumors. Another major effort of the laboratory is to understand how cadherin adhesive function at the cell surface is regulated to control tissue architecture and tumor cell invasion. Loss of E-cadherin expression associated with the epithelial-mesenchymal transition (EMT) is known to promote tumorigenesis and metastasis. However, many tumors and metastases retain E-cadherin expression, and they have found that instead it can be inactivated at the cell surface to cause the loss in function. They have generated a novel class of monoclonal antibodies that activate E-cadherin at the cell surface to restore its adhesive function, and are evaluating whether they reduce tumor invasion and metastasis in animal models. He and his team are also studying how catenins and cancer-associated mutations in E-cadherin affect its ability to switch to the active state and regulate tumor development. The mechanisms by which cadherins and catenins affect tumor growth are varied and complex and offer potential approaches for intervention.

View Bio

Heather Gustafson , PhD

Email: heather.gustafson@seattlechildrens.org

Phone: (206) 884-7339

Dr. Gustafson's career has focused on harnessing existing and developing novel technology platforms that alter macrophage function through environmental manipulation. Her current research, involves engineering several macrophage phenotype targeting methods in order to understand these interactions. Her lab does this through the development of technology platforms that target specific macrophage phenotypes and alter macrophage phenotypes for therapeutic and diagnostic applications. Through the development and use of these technologies they can develop and understanding of how environmental cues impact macrophage function, how macrophage function drives disease progression and how to harness that information to engineer novel technologies to treat disease.

View Bio

Emily Hatch , PhD

Email: ehatch@fredhutch.org

Dr. Emily Hatch studies the structure and dynamics of the mammalian nuclear envelope (NE). Her goals are to understand the molecular mechanisms that initiate NE remodeling in interphase and how defects in NE stability impact cancer development and disease pathogenesis. Her approach combines imaging, biochemical, and genomic techniques with cell-based systems to understand how NE proteins are altered during interphase remodeling, the nuclear and cellular consequences of disrupting the NE barrier, and the long-term effects of NE disruption on cell proliferation and functioning.

View Bio

David Haynor , MD, PhD

Email: haynor@u.washington.edu

Phone: (206) 543-3320

Dr. Haynor's expertise is in the area of radiology, neuroradiology and neurology. His research involves applications of image processing, such as morphometrics, functional MRI, brain perfusion and white matter tract mapping. He is particularly interested in using these techniques to track structural brain differences in fetal alcohol syndrome, disorders of development and neurodegenerative disease.

View Bio

Ross Hays , MD

Email: rhays@chmc.org

Phone: (206) 987-4753

Dr. Hays' clinical interest is pediatric palliative care. His research interests include pediatric disability, medical ethics, and palliative care with focus on health promotion and disease prevention.

View Bio

Chad (Qianchuan) He , PhD

Email: qhe@fredhutch.org

Phone: (206) 667-7068

Dr. He's research is focused on the development of new statistical methods to tackle the high-dimensionality of genomic data, with the aim to achieve sparse models, consistent estimators, and better prediction accuracy. His research is highly interdisciplinary in that it involves statistical theory, bioinformatics, high-performance computing and biomedical sciences

View Bio

Rodney Ho , PhD

Email: Rodneyho@u.washington.edu

Phone: (206) 543-3796

Dr. Ho's research involves drug targeting and translational medicine. He has developed nanomedicine and device-enabled technologies that make anti-infective agents such as HIV, pain and cancer medications more effective and safe.

View Bio

David Hockenbery , MD

Email: dhockenb@fredhutch.org

Phone: (206) 667-4611

Dr. Hockenbery specializes in gastroenterology and the genetic and biochemical mechanisms of apoptosis. Currently his group is focusing on: Investigation of the role of the c-myc transcription factor in bioenergetic regulation in cell growth and division, neoplastic transformation and apoptosis; Analysis of cell signaling and transcriptional responses to nutrient excess, employed in cells susceptible to neoplastic transformation.

View Bio

Noah Hoffman , MD, PhD

Email: ngh2@uw.edu

Phone: (206) 598-7932

Dr. Hoffman's clinical interests and responsibilities include the development and application of software and processes for the collection, management, and display of data generated in the clinical laboratory. His research is focused on creating applications and algorithms to classify medically important microorganisms using biological sequence information.

View Bio

Eric Holland , MD, PhD

Email: eholland@fredhutch.org

Phone: (206) 667-6117

Dr. Holland is a neurosurgeon and brain cancer researcher. His research goal is to address the molecular basis of brain tumors and develop new treatment approaches. His research focuses on developing mouse models of brain cancer that mimic how the disease behaves in patients. He has vast experience in conducting clinical trials in glioma patients and developing imaging strategies to follow mouse brain tumors as they develop a powerful system that is used to test promising new drugs.

View Bio

Leroy (Lee) Hood , MD, PhD

Email: lhood@systemsbiology.org

Phone: (206) 732-1200

The Hood group is integrating biology, technology and computation to create a predictive, personalized, preventive and participatory approach to medicine. His projects center on cancer biology of prostate, glioblastoma and lung cancers, systems approach to prion disease in glioblastoma mouse models, new strategies for obtaining blood biomarkers, and a systems approach to diagnosis and stratification of disease.

View Bio